Land: Nya Zeeland
Språk: engelska
Källa: Medsafe (Medicines Safety Authority)
Desmopressin acetate trihydrate 0.1 mg/mL equivalent to 0.089 mg desmopressin free base
Pharmaco (NZ) Ltd
Desmopressin acetate trihydrate 0.1 mg/mL (equivalent to 0.089 mg desmopressin free base)
0.1 mg/mL
Nasal spray solution
Active: Desmopressin acetate trihydrate 0.1 mg/mL equivalent to 0.089 mg desmopressin free base Excipient: Benzalkonium chloride Citric acid monohydrate Dibasic sodium phosphate dihydrate Sodium chloride Water for injection
Bottle, glass, amber,pre-compression pump 5mL, 5 mL
Prescription
Prescription
PolyPeptide Laboratories AB
Package - Contents - Shelf Life: Bottle, glass, amber,pre-compression pump 5mL - 5 mL - 36 months from date of manufacture stored at or below 25°C protect from light - Bottle, glass, amber,pre-compression pump 6mL - 6 mL - 36 months from date of manufacture stored at or below 25°C protect from light
2005-03-01
ADIN NASAL SPRAY Desmopressin acetate PRESENTATION ADIN 0.1mg/ml nasal spray solution. 1ml nasal spray solution contains 0.1mg desmopressin acetate equivalent to desmopressin 0.089mg. A clear, colourless solution in an amber glass bottle. USES ACTIONS Pharmacotherapeutic group: vasopressin and analogues. ATC code: H01B A02. ADIN nasal spray solution contains desmopressin, a structural analogue of the natural pituitary hormone arginine vasopressin. The difference lies in the desamination of cysteine and substitution of L-arginine by D-arginine. This results in a considerably longer duration of action and a complete lack of pressor effect in the dosages clinically used. PHARMACOKINETICS The bioavailability is about 3-5%. Maximum plasma concentration is reached after approximately one hour. An intranasal dose of 10-20µg provides an antidiuretic effect during 8-12 hours. Desmopressin is excreted mainly in the urine. INDICATIONS ADIN nasal spray solution is indicated for the treatment of central diabetes insipidus and for establishing renal concentration capacity testing. ADIN nasal spray solution is also indicated for the treatment of primary nocturnal enuresis in patients (from 5 years of age) with normal ability to concentrate urine. DOSAGE AND ADMINISTRATION 1 dose of the spray provides 0.1ml, which corresponds to 10µg desmopressin acetate. CENTRAL DIABETES INSIPIDUS Dosage is individual after testing, but normal dosage for adults is 10-20µg 1-2 times daily. For children 5-10µg 1-2 times daily. In the event of signs of water retention/hyponatremia treatment should be interrupted and the dose should be adjusted. PRIMARY NOCTURNAL ENURESIS A clinically effective dose is individual and may vary from 10 to 40µg administered intranasally. A suitable dose is 20µg intranasally at bedtime. Läs hela dokumentet